研究提携_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen,drug development,antibody discovery

top

Please input keywords

ニュース&PR

お問い合わせ

JP

私たちの歩み

管理スタッフ

社会的責任

Antibody Assets

Project Integrum

Antibody discovery platforms

Clinical pipeline

Preclinical pipeline

動物・細胞モデル

Humanized animal models

KO mouse models

Immunodeficient mice/rats

Disease mouse models

Pharmacology service

Therapeutic area

Types of services

ゲノム編集

By technologies

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Microbial detection

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Stock Information

Financial Reports

Listing Documents

Announcements & Notices

Corporate Governance

Investor Calendar

研究提携

オープンイノベーションによる革新的な新薬の研究開発

Biocytogen is actively seeking partnerships for Project Integrum-derived antibody assets and RenMice-based antibody discovery platforms. Biocytogen is committed to advancing novel drug R&D to benefit patients as soon as possible.

Collaboration Models

Antibody Out-licensing

Antibody Co-Development

Antibody Transfer

Technology Platform Out-licensing

Various drug modalities

Monoclonal Antibody

Bispecific Antibody

Established partnerships

103 therapeutic antibody co-development/out-licensing/transfer agreements

47 target-nominated RenMice licensing projects

5 pipeline-based co-development

Disclosed Partners

Worldwide antibody assets or platform partners include Gilead, Merck KGaA, Janssen, Xencor, ADC Therapeutics, Neurocrine Biosciences, Radiance Biopharma, RemeGen and BeiGene.

Contact us for antibody assets and platforms partnership opportunities at BD-Licensing@biocytogen.com.